Evommune (EVMN) Total Current Liabilities (2024 - 2026)

Evommune (EVMN) has 3 years of Total Current Liabilities data on file, last reported at $10.6 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $10.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $17.9 million, down 36.0% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $10.6 million, down from $17.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for EVMN reached as high as $28.0 million in Q4 2024 and fell as low as $10.4 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $16.7 million across 3 years, with a median of $14.3 million in 2025.
• On a YoY basis, Total Current Liabilities climbed as much as 36.0% in 2025 and fell as far as 36.0% in 2025.
• Year by year, Total Current Liabilities stood at $28.0 million in 2024, then sank by 36.0% to $17.9 million in 2025, then plunged by 40.8% to $10.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $10.6 million in Q1 2026, $17.9 million in Q4 2025, and $10.4 million in Q3 2025.